IPF in a World with COVID-19
The Potential for Anti-Fibrotic Therapies to Combat Fibrosis From SARS-CoV-2 Infection

8:00 am Chair’s Opening Remarks: IPF in a World with COVID-19

  • Fernando Martinez Chief Division of Pulmonary & Critical Care Medicine, Weill Cornell Medicine

8:20 am Radiology of COVID-19

  • Mary Salvatore Associate Professor – Radiology, Columbia University Medical Center

8:40 am Mechanisms of COVID-19 Induced Alveolar Injury & Fibrogenesis

  • Gisli Jenkins NIHR Research Professor , University of Nottingham

9:00 am The Clinical Picture & Follow up of SARS-CoV-2

  • Paolo Spagnolo Associate Professor of Respiratory Medicine, Director, School of Specialization in Respiratory Medicine , University of Padua

9:20 am Group Q&A & Panel Discussion “What is the Risk to IPF Patients?”

  • Fernando Martinez Chief Division of Pulmonary & Critical Care Medicine, Weill Cornell Medicine
  • Mary Salvatore Associate Professor – Radiology, Columbia University Medical Center
  • Gisli Jenkins NIHR Research Professor , University of Nottingham
  • Paolo Spagnolo Associate Professor of Respiratory Medicine, Director, School of Specialization in Respiratory Medicine , University of Padua

10:00 am Online Speed Networking

10:45 am
Morning Break & Networking

Preclinical & Early Translational Track

Late Translational & Clinical Track

Mechanistic Understanding & Recapitulation in Vitro

Predicting Mortality with Biomarkers

11.00 The Impact of Nintedanib on the Single Cell Seq Profile of Macrophage Populations

Karim Christian el Kasmi, Laboratory Head, Boehringer Ingelheim

11.00 An Update from PROLIFIC Biomarker Consortium

Peter Schafer, Executive Director, Translational Medicine, Bristol Myers Squibb

11.45 From in vitro to ‘In Matrico’: Human Fibrotic Lung Extracellular Matrix Substrates Increase the Relevance of Cell-Based IPF Models for Anti-Fibrotic Drug Development

John O’Neill, Co-Founder & Chief Scientific Officer, Xylyx Bio

11.45 Session Held by ERT

12.00 Mechanisms of Lung Protection by Innate Immunity Modulators

Andrei Gudkov, Chief Scientific Officer, Genome Protection, Professor of Oncology, Roswell Park Comprehensive Cancer Center

12.00 Biomarkers for Managing ILDs

Eric White, Director, Clinical Development, ILD Therapeutic Area, Boehringer Ingelheim & Adjunct Professor, University of Michigan

12:30 pm
Lunch Break & Roundtable Discussions

Preclinical & Early Translational Track

Late Translational & Clinical Track

Fibrosis Biology & Translational Research

Clinical Trial Endpoints – Old & New

1.30 Phenotypes, Genotypes, & Subtypes of Fibroblasts in Lung Fibrosis

Dianhua Jiang, Professor of Medicine & Biomedical Sciences, Scientific Director, Pulmonary Fibrosis Research Center, Cedars Sinai Medical Center

1.30 Session Held by Nordic Bioscience

2.00 Found in Translation: Targeting Collagen I Protein Synthesis as a Novel Therapeutic Approach for IPF

Iris Alroy, Vice President of Research & Development, Anima Biotech

2.00 The Utility of PET-based Molecular Imaging in IPF

Tejaswini Kulkarni, Assistant Professor, Pulmonary & Critical Care Medicine, UAB

2.30 Epithelial Protection/Preservation Through IRE1α Inhibition

Tim Pelura, Chief Executive Officer, OptiKira

 

2.15 Forced Vital Capacity as a Clinical Trial Endpoint: PROs & CONs

Jack Stauffer, Senior Medical Director, Genentech

2.45 Extended Q&A

3:00 pm
Afternoon Break & Networking

What do we Know & What are we Trying to Achieve? Key Pathways, Treatable Traits, Tool Compounds

3:30 pm Reviewing Evidence & Understanding of “Anti-Fibrotic” Compounds Clinically: Do we Have “Anti-Fibrotic” Drugs & How are They ‘Anti- Fibrotic”?

  • Cory Hogaboam Professor of Medicine, Cedars-Sinai Medical Center

4:00 pm Panel Discussion: Mechanistic Interrogation of Existing Drugs

  • Cory Hogaboam Professor of Medicine, Cedars-Sinai Medical Center
  • Eric White Director, Clinical Development, ILD Therapeutic Area, Boehringer Ingelheim & Adjunct Professor, University of Michigan
  • David Rowlands Associate Director, Respiratory Biology, NIBR

Scientific Foundations for IPF Targets
Advancing the Next Generation of Disease Modifying Candidates

4:30 pm The Impact of Nintedanib on the Single Cell Seq Profile of Macrophage Populations

4:30 pm How Three Lakes Foundation is Accelerating Therapies for Pulmonary Fibrosis

5:00 pm Implications of the Insights from the IPF Cell Atlas for Drug Development

  • Naftali Kaminski Section Chief, Pulmonary, Critical Care & Sleep Medicine, Yale School of Medicine

5:30 pm Day One Ends